How many stocks are there of Crossject?
The current number of stocks of Crossject is 36.76 M undefined.
Crossject Stocks 2024
Crossject Stocks
36.76 M
Crossject Dividend yield
Ticker
ALCJ.PA
ISIN
FR0011716265
WKN
A1XEH4
In 2024, Crossject had 36.76 M outstanding stocks, a 0% change from the 36.76 M stocks in the previous year.
The Crossject Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2026e | 36.76 |
| 2025e | 36.76 |
| 2024e | 36.76 |
| 2023 | 36.76 |
| 2022 | 36.52 |
| 2021 | 26.19 |
| 2020 | 24.02 |
| 2019 | 20.32 |
| 2018 | 13.68 |
| 2017 | 9.3 |
| 2016 | 7.69 |
| 2015 | 6.97 |
| 2014 | 6.97 |
| 2013 | 4.41 |
| 2012 | 2.66 |
| 2011 | 2.66 |
| 2010 | 2.66 |
Crossject Aktienanalyse
What does Crossject do?
Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Crossject's Shares Outstanding
Crossject's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Crossject’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Crossject’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Crossject’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Crossject Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Crossject are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Crossject evolved in recent years?
The number of shares of Crossject has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Crossject as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Crossject?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Crossject pay?
Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.
What is the dividend yield of Crossject?
The current dividend yield of Crossject is .
When does Crossject pay dividends?
Crossject pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Crossject?
Crossject paid dividends every year for the past 0 years.
What is the dividend of Crossject?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Crossject located?
Crossject is assigned to the 'Health' sector.
Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Crossject from 5/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/19/2024.
When did Crossject pay the last dividend?
The last dividend was paid out on 5/19/2024.
What was the dividend of Crossject in the year 2023?
In the year 2023, Crossject distributed 0 EUR as dividends.
In which currency does Crossject pay out the dividend?
The dividends of Crossject are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Crossject
Our stock analysis for Crossject Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
